Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Real-time Estimate Cboe BZX 18:56:11 24/05/2024 BST 5-day change 1st Jan Change
809 USD +0.06% Intraday chart for Eli Lilly and Company +5.01% +38.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care MT
Top Midday: Intuit, Workday Shares Tumble on Lowered Guidance; Ozempic Reduces Kidney Disease Events, Deaths From Cardiovascular Causes; NHTSA Finds 9 Additional Incidents Tied to Waymo MT
Eli Lilly More Than Doubles Investment in Indiana Manufacturing Site to $9 Billion MT
News Highlights : Top Company News of the Day - Friday at 11 AM ET DJ
Eli Lilly More Than Doubles Investment in Indiana Manufacturing Site to $9 Billion MT
Eli Lilly More Than Doubles Investment in Indiana Manufacturing Site to $9 Billion MT
Eli Lilly: invests $5.3 billion in its Indiana site CF
Lilly invests further $5.3 billion in new Indiana site as obesity drug demand soars RE
Eli Lilly and Company Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production forirzepatide and Pipeline Medicines CI
Jefferies Adjusts Price Target on Eli Lilly to $925 From $915 MT
Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln RE
Radar Therapeutics announced that it has received $13.4 million in funding from NFX Capital Management, LLC, Eli Lilly and Company, Biovision Ventures, KDT Ventures LLC, Pear Ventures Management, LLC, Bevc Management, Llc, and other investors CI
Swiss Equities Tumble as UK Inflation Data Dampens June Rate Cut Hopes MT
Eli Lilly Reports Positive Trial Results for Crohn's Disease Treatment MT
China Grants Green Light to Eli Lilly's Diabetes Treatment MT
Eli Lilly Wins Chinese Approval for Diabetes Drug MT
Australia to ban knock-offs of popular weight-loss drugs Ozempic, Mounjaro RE
Health Care Up as Eli Lilly Hits Record High - Health Care Roundup DJ
Two US asset managers launch weight-loss ETFs RE
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... Our Logo
Eli Lilly: conclusive trial in Crohn's disease CF
Central bankers try to reason with investors Our Logo
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Eli Lilly and Company's Phase 3 Study of Mirikizumab to Treat Crohn's Disease Achieves 'Meaningful Improvements' MT
Eli Lilly Reports More than 50% Remission Rate in Crohn's Treatment Trial DJ
Chart Eli Lilly and Company
More charts
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
808.4 USD
Average target price
850.8 USD
Spread / Average Target
+5.24%
Consensus
  1. Stock Market
  2. Equities
  3. LLY Stock
  4. News Eli Lilly and Company
  5. Eli Lilly and : , Incyte Say Baricitinib Meets Phase 3 Efficacy Endpoint in Treating Baldness